BONUSCAP-ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000HVB5UZ7

Real-time Bid/Ask 06:15:56 2024-06-28 EDT
760 EUR / 767.64 EUR +0.72% Intraday chart for BONUSCAP-ZERTIFIKAT - ROCHE GS
Current month+11.47%
1 month+11.52%
Date Price Change
24-06-28 755.9 -0.32%
24-06-27 758.3 +0.19%
24-06-26 756.9 -1.84%
24-06-25 771.1 -0.57%
24-06-24 775.4 +1.40%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 03:59 am

More quotes

Static data

Product typeBonus- und Teilschutz-Zertifikate
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HVB5UZ
ISINDE000HVB5UZ7
Date issued 2021-09-28
Strike 384.7 CHF
Maturity 2026-09-21 (816 Days)
Parity 0.34 : 1
Emission price 1,000
Emission volume N/A
Settlement Beides
Currency EUR

Technical Indicators

Highest since issue 1,138
Lowest since issue 610.9
Spread 7.63
Spread %1.00%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.04%
Consensus